Mission Statement, Vision, & Core Values (2026) of Chengdu Easton Biopharmaceuticals Co., Ltd.

Meet Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS), founded in 2009, a rapidly growing Chinese pharma player focused on R&D, manufacturing and commercialization of APIs and finished dosage forms-best known for APIs like Apixaban and Apalutamide-that reported revenue of about 1.35 billion CNY in 2024 (a year‑over‑year rise of 20.82%) and has broadened its global reach via strategic deals (including exclusive overseas authorization with Kexing Biopharm for Apalutamide in more than ten countries), while market capitalization surged to 9.82 billion CNY as of December 17, 2025 (up 63% year‑on‑year), reflecting a mission-driven emphasis on innovation, quality, integrity and collaborative expansion as the company pursues its vision of becoming a leading global biopharmaceutical firm.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Intro

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) is a China-based pharmaceutical company founded in 2009, focused on research, development, manufacturing, and commercialization of finished dosage forms (capsules, tablets, injections) and active pharmaceutical ingredients (APIs). Key API offerings include Apixaban (cardiovascular) and Apalutamide (oncology). The company has broadened its global reach via strategic authorizations and partnerships, including an exclusive agreement with Kexing Biopharm for overseas commercialization of Apalutamide tablets in over ten countries. For further financial analysis, see Breaking Down Chengdu Easton Biopharmaceuticals Co., Ltd. Financial Health: Key Insights for Investors.

• Founded: 2009
• Core products: Finished dosage forms (capsules, tablets, injections) and APIs
• Notable APIs: Apixaban, Apalutamide
• Strategic partnership: Exclusive overseas commercialization with Kexing Biopharm

To discover, develop, and deliver high-quality, affordable pharmaceutical therapies that address major unmet medical needs domestically and internationally, while maintaining rigorous quality, compliance, and patient-centricity.

To be a globally recognized biopharmaceutical innovator from China, transforming scientific advances into accessible therapies across cardiovascular and oncological indications and expanding vertically along the value chain from API to finished products and commercialization.

• Patient-first: Prioritize safety, efficacy, and accessibility of treatments.
• Scientific excellence: Invest in rigorous R&D and evidence-based development.
• Regulatory integrity: Adhere to high-quality manufacturing and compliance standards.
• Global partnership: Leverage collaborations to accelerate market access and scale.
• Sustainable growth: Balance commercial performance with long-term innovation.

• Advance lead APIs (Apixaban, Apalutamide) through global registrations and commercialization.
• Scale finished dosage manufacturing capacity and GMP compliance for export markets.
• Expand licensing and co-commercialization deals to increase international footprint.
• Allocate resources to targeted R&D for cardiovascular and oncology portfolios.

• High unmet need and market potential in cardiovascular and oncology segments favor prioritization of Apixaban and Apalutamide.
• Scaling finished-dosage capability supports margin expansion and export-driven revenue growth.
• Partnerships accelerate regulatory access and shared commercialization risk in international markets.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Overview

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) is a vertically integrated pharmaceutical company focused on the research, development, manufacture and commercialization of active pharmaceutical ingredients (APIs) and finished dosage forms. The company's strategic direction centers on innovation-driven R&D, rigorous quality and compliance, global market expansion and partnership-driven distribution to broaden patient access to effective therapies.

Mission Statement

• Dedicate resources to the research, development, manufacturing and commercialization of pharmaceutical products with measurable clinical benefit.
• Provide high-quality APIs and finished dosage forms to meet diverse patient needs across therapeutic areas.
• Emphasize continuous innovation in R&D processes to deliver effective, safe and manufacturable pharmaceutical solutions.
• Enhance global healthcare by expanding product offerings and entering new geographic markets.
• Maintain rigorous quality systems and full regulatory compliance across all operations and manufacturing sites.
• Build strategic partnerships to facilitate global distribution and accelerate commercialization.

Vision

• Become a globally recognized biopharmaceutical enterprise delivering trusted APIs and finished products that improve patient outcomes.
• Lead in selected therapeutic niches by translating scientific innovation into scalable, quality-controlled commercial products.
• Create long-term stakeholder value by balancing robust R&D investment, disciplined manufacturing excellence and responsible governance.

Core Values

• Scientific Rigor - evidence-driven discovery and validation at every stage.
• Quality First - uncompromising GMP and regulatory compliance.
• Patient Centricity - prioritize safety, efficacy and access for patients.
• Collaboration - strategic partnerships with academia, CROs, CMOs and distributors.
• Integrity - transparent governance, environmental responsibility and ethical conduct.
• Continuous Improvement - operational excellence and lean, efficient processes.

Key Operational and Strategic Metrics

Strategic Priorities and Quantifiable Targets

• Scale commercial footprint: target double-digit annual export growth by expanding distributor partnerships across 10+ new countries within 3 years.
• R&D productivity: increase pipeline output with a goal of advancing 3-5 candidates to registration-phase within 5 years.
• Quality and capacity: add manufacturing capacity to increase API annual output by 30-50% to meet growing global demand.
• Financial discipline: pursue sustainable margin expansion through process optimization and higher-value finished product sales.

For a focused review of the company's financial performance, ratios and investor-oriented details, see: Breaking Down Chengdu Easton Biopharmaceuticals Co., Ltd. Financial Health: Key Insights for Investors

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Mission Statement

• Develop and commercialize high-quality biologics and small-molecule therapeutics addressing unmet medical needs.
• Prioritize patient-centricity: safety, efficacy, affordability, and equitable access.
• Invest consistently in R&D and manufacturing excellence to ensure long-term product supply and innovation capacity.
• Build strategic partnerships and international distribution channels to accelerate global reach.

• Global expansion: targeted entry into >15 international markets through licensing and partnerships.
• Pipeline ambition: advance a diversified pipeline of biologics and niche specialty drugs to commercialization.
• Quality leadership: achieve and maintain global regulatory approvals (NMPA, EMA, FDA) for key assets.
• Sustainability: balance growth with ESG practices, including responsible manufacturing and community health initiatives.

• R&D excellence: sustained investment in biologics platforms, biomarker-driven development, and clinical trial capacity to reduce time-to-market.
• Manufacturing scale-up: GMP-compliant facilities and capacity expansion to secure supply for domestic and export markets.
• Regulatory and quality strategy: pursue approvals across major jurisdictions to validate product safety and efficacy globally.
• Collaborations and licensing: selective partnerships to accelerate access, co-development, and commercialization outside China.

• Patients: deliver measurable improvements in clinical outcomes and access to therapies.
• Investors: drive sustainable revenue growth, margin improvement, and transparent governance.
• Employees: foster a culture of scientific rigor, compliance, and continuous learning.
• Partners and regulators: uphold high standards of quality, safety, and ethical collaboration.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Vision Statement

Mission Statement

Core Values

• Integrity & Transparency - Upholding ethical conduct, compliance, and clear stakeholder communication across operations and reporting.
• Innovation - Prioritizing R&D investment to advance new modalities and shorten time‑to‑market for critical therapies.
• Quality - Ensuring all products meet stringent GMP, regulatory, and internal quality standards.
• Collaboration - Pursuing strategic partnerships (academic, CROs, biotech, and global distributors) to scale development and commercialization.
• Customer Focus - Centering patient needs in product design, access programs, and post‑market surveillance.
• Sustainability - Embedding environmental, social, and governance (ESG) practices to promote long‑term value creation.

Strategic Pillars Aligned to Vision & Values

• R&D Leadership: Accelerate clinical pipeline through targeted biologics and novel small molecules, emphasizing oncology and autoimmune disease niches.
• Quality & Compliance: Maintain full GMP certification for manufacturing sites and strengthen pharmacovigilance capabilities.
• Global Expansion: Enter select international markets via licensing and distribution partnerships to increase patient access.
• ESG & Sustainability: Implement resource‑efficient manufacturing and reduce carbon intensity across operations.
• Stakeholder Trust: Transparent investor reporting, ethical supply‑chain practices, and patient engagement programs.

Key Operational & Financial Highlights (Selected Metrics)

How Core Values Translate into Measurable Actions

• Integrity & Transparency: Quarterly investor disclosures, independent ESG audits, and compliance training completed by >98% of employees in 2023.
• Innovation: Increased R&D headcount by 35% year‑over‑year; 6 candidates in clinic as of Dec 2023, targeting pivotal studies in 2024-2026.
• Quality: Zero major GMP observations in recent inspections; product release compliance rate >99.5% in 2023.
• Collaboration: Six active strategic alliances with CROs, academic centers, and regional distributors; licensing deals contributing 12% of 2023 revenue.
• Customer Focus: Patient support programs rolled out in three therapeutic areas, reaching >18,000 beneficiaries in 2023.
• Sustainability: Energy‑efficiency upgrades across manufacturing sites, reducing energy consumption per unit produced by ~9% in 2023.